Utsikt
Senior Member (Voting Rights)
I struggle to keep up with the names. Can you remind me who Jo is?I am working on some paragraphs now. And Jo should be round for tea tomorrow!
I struggle to keep up with the names. Can you remind me who Jo is?I am working on some paragraphs now. And Jo should be round for tea tomorrow!
Can you remind me who Jo is?
We also had a data technician called Jo.
Any suggestions on topics for background reading/learning for those of us not versed in this stuff who want to have the best chance of understanding what you’ll be talking about?I am working on some paragraphs now. And Jo should be round for tea tomorrow!
It sounds as if cytokines, complement proteins/pathways and the tumour necrosis factor superfamily would be useful areas here?
Everything… ok I shall continue with my crash course in blaggers biology thenProbably everything. But a lot of it is fairly familiar stuff and easy to follow I think.
It sounds as if cytokines, complement proteins/pathways and the tumour necrosis factor superfamily would be useful areas here?
I think otherwise, in quite a major way! I'm really excited about your and Jo C's paper but when it appears, as things stand, I really am going to be reading it thinking, 'What? What?'Probably everything. But a lot of it is fairly familiar stuff and easy to follow I think.
Will there be diagrams?
I don't know anything about B cells, T cells, cytokines, and whatnot except that they exist.
Yay!No, only buns and lemonade.
@Sasha this youtube account (https://www.youtube.com/@AKLECTURES) has been a great resource for me to learn about topics in biochemistry, immunology, etc. when I wasn't physically able to take those classes.
Thanks, @jnmaciuch, I'll have a look!
I’ll send them in the mail, please allow 7-10 business days.You have to provide your own buns and lemonade though.
Our study is limited by the small sample size and the potentially heterogeneous populations of B cells sampled.
Sorting B cells into naive, memory, and atypical B cells prior to performing repertoire sequencing would substantially improve the inferences drawn from future repertoire sequencing studies.
Given the emerging evidence of altered serum antibody repertoires targeting microbiome antigens (56) in ME/CFS patients, future studies should also consider sequencing IgA, as well as IgM and IgG isotypes.
Future repertoire sequencing studies in ME/CFS where repertoires from patients and controls are sampled prior to and following vaccination could shed light on whether B-cell responses to antigenic challenge are impaired in ME/CFS.
Do you mind listing what those 3 studies were? The first thing that comes to mind to check is whether all of them were done after Covid started.I'm really interested in what is going on behind the scenes with IGHV3-30. Is anything happening? Three studies with a positive result on something so specific feels to me like an "all hands on deck" moment.